A Phase 1/2 Study of Lurbinectedin to Treat People With FET-Fused Tumors

Full Title

Purpose

Researchers in this study want to find the best dose of lurbinectedin to treat cancer in children and adults. They also want to see how well this drug works. The people in this study have Ewing sarcoma or other solid tumors that keep growing after treatment. In addition, their cancers contain a genetic change called a FET fusion.

A FET fusion includes the “FET” genes FUS, EWSRI, or TAF15. It may be seen in people with:

• Ewing sarcoma
• Desmoplastic small round cell tumor
• Clear cell sarcoma
• Myxoid liposarcoma
• Myxoid chondrosarcoma
• Sclerosing epithelioid fibrosarcoma
• Angiomatoid fibrous histiocytoma
• Myoepithelioma

Lurbinectedin is a type of drug called an alkylating agent. These drugs target cancer cells and interfere with their DNA (genetic material) to slow or stop cell growth. Lurbinectedin is given intravenously (by vein).

Contact

For more information and to see if you or your child can join this study, please call 833-MSK-KIDS.